U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 199

1.
Bosutinib Stimulates Macrophage Survival, Phagocytosis, and Intracellular Killing of Bacteria
Ronni A. G. da Silva, Claudia J. Stocks, Guangan Hu, Kimberly A. Kline, Jianzhu Chen
ACS Infect Dis. 2024 May 10; 10(5): 1725–1738. Published online 2024 Apr 11. doi: 10.1021/acsinfecdis.4c00086
PMCID:
PMC11091880
AbstractArticlePDF–5.3M
2.
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
Akriti G Jain, Quinto Gesiotto, Somedeb Ball, Lisa Nodzon, Amanda Rodriguez, Onyee Chan, Eric Padron, Andrew Kuykendall, Rami Komrokji, David A. Sallman, Jeffrey E Lancet, Javier Pinilla-Ibarz, Kendra Sweet
Ann Hematol. 2024; 103(6): 1941–1945. Published online 2024 Apr 18. doi: 10.1007/s00277-024-05760-6
PMCID:
PMC11090947
AbstractArticlePDF–662K
3.
Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921
Erica Brivio, Edoardo Pennesi, Marieke E. Willemse, Alwin D.R. Huitema, Yilin Jiang, Harm D.R. van Tinteren, Vincent H.J. van der Velden, Berna H. Beverloo, Monique L. den Boer, Lukas A.J. Rammeloo, Chad Hudson, Nyla Heerema, Karey Kowalski, Huadong Zhao, Luke Kuttschreuter, Francisco J. Bautista Sirvent, Andrew Bukowinski, Carmelo Rizzari, Jessica Pollard, Laura Murillo-Sanjuán, Matthew Kutny, Sara Zarnegar-Lumley, Michele Redell, Stacy Cooper, Yves Bertrand, Arnaud Petit, Julie Krystal, Markus Metzler, Donna Lancaster, Jean-Pierre Bourquin, Jayashree Motwani, Inge M. van der Sluis, Franco Locatelli, Michael E. Roth, Nobuko Hijiya, Christian M. Zwaan
J Clin Oncol. 2024 Mar 1; 42(7): 821–831. Published online 2023 Nov 30. doi: 10.1200/JCO.23.00897
PMCID:
PMC10906575
AbstractArticlePDF–1.2M
4.
Dose-dependent, non-pigmenting fixed drug eruption with eczematous lesions induced by bosutinib: case report
Joohyung Youh, Yasuyuki Yamaguchi, Tsugumichi Kawamura, Daichi Hoshina
Pan Afr Med J. 2023; 46: 95. Published online 2023 Dec 1. doi: 10.11604/pamj.2023.46.95.42208
PMCID:
PMC10891373
AbstractArticlePDF–397K
5.
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
Dehua Zhao, Xiaoqing Long, Jisheng Wang
BMC Pharmacol Toxicol. 2024; 25: 20. Published online 2024 Feb 23. doi: 10.1186/s40360-024-00741-x
PMCID:
PMC10885429
AbstractArticlePDF–1.3M
6.
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study
Gianantonio Rosti, Tim H. Brümmendorf, Björn T. Gjertsen, Pilar Giraldo-Castellano, Fausto Castagnetti, Carlo Gambacorti-Passerini, Thomas Ernst, Huadong Zhao, Luke Kuttschreuter, Simon Purcell, Francis J. Giles, Andreas Hochhaus
Leukemia. 2024; 38(1): 126–135. Published online 2023 Nov 25. doi: 10.1038/s41375-023-02080-y
PMCID:
PMC10776383
AbstractArticlePDF–932K
7.
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study
Jorge E. Cortes, Jeff H. Lipton, Vamsi Kota, Fausto Castagnetti, Sarit Assouline, Tim H. Brümmendorf, Eric Leip, Andrea Viqueira, Carlo Gambacorti-Passerini
Haematologica. 2023 Dec 1; 108(12): 3454–3459. Published online 2023 Jul 13. doi: 10.3324/haematol.2022.281944
PMCID:
PMC10690913
ArticlePDF–207K
8.
Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia
May Garrett, Beverly Knight, Jorge E. Cortes, Michael W. Deininger
Cancer Med. 2023 Sep; 12(17): 17981–17992. Published online 2023 Aug 8. doi: 10.1002/cam4.6439
PMCID:
PMC10524044
AbstractArticlePDF–1.2M
9.
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
Susanne Isfort, Kirsi Manz, Lino L. Teichmann, Martina Crysandt, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Alexander Kiani, Joachim R. Göthert, Thomas Illmer, Philippe Schafhausen, Haifa Kathrin Al-Ali, Frank Stegelmann, Mathias Hänel, Tim Pfeiffer, Aristoteles Giagounidis, Georg-Nikolaus Franke, Steffen Koschmieder, Alice Fabarius, Thomas Ernst, Mareille Warnken-Uhlich, Uta Wolber, Denise Kohn, Markus Pfirrmann, Dominik Wolf, Tim H. Brümmendorf, for the German CML study group
Ann Hematol. 2023; 102(10): 2741–2752. Published online 2023 Aug 18. doi: 10.1007/s00277-023-05394-0
PMCID:
PMC10492675
AbstractArticlePDF–1.7M
10.
Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study
Jing Huang, Juanjuan Cai, Qingqing Ye, Qiaoying Jiang, Huan Lin, Lun Wu
BMJ Open. 2023; 13(8): e071456. Published online 2023 Aug 3. doi: 10.1136/bmjopen-2022-071456
PMCID:
PMC10401248
AbstractArticlePDF–710K
11.
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial
Delphine Réa, Carla Boquimpani, Michael J. Mauro, Yosuke Minami, Alex Allepuz, Vikalp Kumar Maheshwari, Denise D’Alessio, Ying Wu, Rachael Lawrance, Sarunas Narbutas, Giora Sharf, Andreas Hochhaus
Leukemia. 2023; 37(5): 1060–1067. Published online 2023 Apr 14. doi: 10.1038/s41375-023-01888-y
PMCID:
PMC10169655
AbstractArticlePDF–1.4M
12.
Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization
Ivan Civettini, Laura Antolini, Filippo Brioschi, Giovanni Paolo Maria Zambrotta, Veronica Guglielmana, Carlo Gambacorti‐Passerini
Cancer Med. 2023 Apr; 12(8): 9662–9667. Published online 2023 Apr 11. doi: 10.1002/cam4.5923
PMCID:
PMC10166942
AbstractArticlePDF–666K
13.
Small Molecule Inhibitor Against Onco-mucins Disrupts Src/FosL1 Axis to Enhance Gemcitabine Efficacy in Pancreatic Ductal Adenocarcinoma
Chunmeng Zhang, Pranita Atri, Palanisamy Nallasamy, Seema Parte, Sanchita Rauth, Rama Krishna Nimmakayala, Saravanakumar Marimuthu, Ramakanth Chirravuri-Venkata, Rakesh Bhatia, Sushanta Halder, Ashu Shah, Jesse L Cox, Lynette Smith, Sushil Kumar, Jason M Foster, Rakesh Kukreja, Parthasarathy Seshacharyulu, Moorthy P. Ponnusamy, Surinder K. Batra
Cancer Lett. Author manuscript; available in PMC 2023 Dec 28.
Published in final edited form as: Cancer Lett. 2022 Dec 28; 551: 215922. Published online 2022 Sep 19. doi: 10.1016/j.canlet.2022.215922
PMCID:
PMC10124158
AbstractArticlePDF–2.8M
14.
Management of chronic myeloid leukemia in 2023 – common ground and common sense
Jayastu Senapati, Koji Sasaki, Ghayas C. Issa, Jeffrey H. Lipton, Jerald P. Radich, Elias Jabbour, Hagop M. Kantarjian
Blood Cancer J. 2023 Dec; 13(1): 58. Published online 2023 Apr 24. doi: 10.1038/s41408-023-00823-9
PMCID:
PMC10123066
AbstractArticlePDF–802K
15.
Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects
Pouya Dehghankelishadi, Parisa Badiee, Michelle F. Maritz, Nicole Dmochowska, Benjamin Thierry
J Nanobiotechnology. 2023; 21: 102. Published online 2023 Mar 21. doi: 10.1186/s12951-023-01848-9
PMCID:
PMC10028769
AbstractArticlePDF–6.8M
16.
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E. Cortes, Timothy P. Hughes, Jane F. Apperley, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, Valentin García-Gutiérrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J. Mauro
Leukemia. 2023; 37(3): 617–626. Published online 2023 Jan 30. doi: 10.1038/s41375-023-01829-9
PMCID:
PMC9991909
AbstractArticlePDF–1.4M
17.
Rapid LC-MS/MS Bosutinib Quantification with Applications in Metabolic Stability Estimation
Mohamed W. Attwa, Mohammed M. Alanazi
Molecules. 2023 Feb; 28(4): 1641. Published online 2023 Feb 8. doi: 10.3390/molecules28041641
PMCID:
PMC9965169
AbstractArticlePDF–3.0M
18.
Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study
Junichiro Yuda, Noriko Doki, Hiroshi Matsuoka, Takafumi Yokota, Akihiro Tomita, Naoto Takahashi, Itaru Matsumura, Kohmei Kubo, Tatsunori Goto, Keita Kirito, Akio Maki, Makoto Aoki, Alex Allepuz, Yosuke Minami
Cancer Med. 2023 Feb; 12(3): 2990–2998. Published online 2022 Sep 27. doi: 10.1002/cam4.5212
PMCID:
PMC9939084
AbstractArticlePDF–319K
19.
A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors
Nagla Abdel Karim, Asad Ullah, Hongkun Wang, Mahran Shoukier, Steven Pulliam, Ahmed Khaled, Nikhil Patel, John C. Morris
Curr Oncol. 2022 Dec; 29(12): 9461–9473. Published online 2022 Dec 3. doi: 10.3390/curroncol29120744
PMCID:
PMC9776616
AbstractArticlePDF–1.2M
20.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Delphine Réa, Michael J. Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F. Apperley, Andre Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Koji Sasaki, Lynette Chee, Valentin García-Gutiérrez, Jorge E. Cortes, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus
Blood. 2021 Nov 25; 138(21): 2031–2041. Published online 2021 Aug 20. doi: 10.1182/blood.2020009984
PMCID:
PMC9728405
AbstractArticle

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed Central (PMC)
Support Center